| Laboratory parameter profiles among patients with cystic fibrosis. | |
| | |
MedLine Citation:
|
PMID: 16829217 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Clinical trials in cystic fibrosis (CF) currently use laboratory-specific reference ranges to evaluate chemistry and hematology measurements. Laboratory-specific normal reference ranges may not accurately reflect what is abnormal but clinically insignificant among CF patients. METHODS: To address this concern, data from the Phase III trial of inhaled tobramycin in CF patients was used to describe the distribution and variability of laboratory parameters. The laboratory specimens were analyzed at a central laboratory after being obtained at baseline and throughout the 24-week trial. RESULTS: At the time of entry into the clinical trial, 91% (463 of 508) of patients had at least a single value outside the normal range. Liver function tests (AST, ALT) were above the normal range in 16% and 12% of the patients respectively, with 2.4% of patients having an AST>2.0 times the upper limit of normal. Of the 243 patients on placebo, 242 (99.6%) had at least one laboratory parameter that changed from normal to abnormal during the 24-week follow-up period. Of those same placebo patients, 11.5% (N=28) had a laboratory parameter change from a Common Toxicity Criteria (CTC) grade 0 to grade 2 or higher during follow-up. CONCLUSIONS: Patients with CF frequently have laboratory values outside the normal range and have significant longitudinal variability of laboratory values. Interpretation of adverse events in the clinical trial setting may be complicated by the underlying high rates of some laboratory abnormalities in the CF population. This data was presented in poster format at the American Thoracic Society International Conference, Atlanta, USA, 2002, appearing subsequently in the Conference proceedings [Goss CH, Mayer-Hamblett N, Yunker A, Waltz DA, Kronmal RA, Ramsey BW. Laboratory parameter profiles among patients with cystic fibrosis. Am J Rep Crit Care Med 2002;165(8):A283]. |
| | |
Authors:
|
Christopher H Goss; Nicole Mayer-Hamblett; Richard A Kronmal; Judy Williams; Bonnie W Ramsey |
Related Documents
:
|
16702447 - Review of the abdominal manifestations of cystic fibrosis in the adult patient. 7562277 - Cystic fibrosis-associated colitis and fibrosing colonopathy. 18757147 - Factors predictive of complicated or severe alcohol withdrawal in alcohol dependent inp... 17942657 - Cystic fibrosis patient with burkholderia pseudomallei infection acquired in brazil. 19190717 - Hypertriglyceridemia-induced pancreatitis created by oral estrogen and in vitro fertili... 18452507 - Tissue ghrelin level and gastric emptying rate in adult patients with celiac disease. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2006-07-07 |
Journal Detail:
|
Title: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society Volume: 6 ISSN: 1569-1993 ISO Abbreviation: J. Cyst. Fibros. Publication Date: 2007 Apr |
Date Detail:
|
Created Date: 2007-03-19 Completed Date: 2007-06-19 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101128966 Medline TA: J Cyst Fibros Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 117-23 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of Washington Medical Center, Seattle, WA 98195, USA. goss@u.washington.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Alanine Transaminase / metabolism Anti-Bacterial Agents / therapeutic use* Aspartate Aminotransferases / metabolism Child Clinical Trials, Phase III as Topic Cross-Sectional Studies Cystic Fibrosis / therapy* Cystic Fibrosis Transmembrane Conductance Regulator / genetics, metabolism Double-Blind Method Female Humans Laboratory Techniques and Procedures Liver Function Tests Longitudinal Studies Male Placebos Reference Values Tobramycin / therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
MO1-RR00037/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/CFTR protein, human; 0/Placebos; 126880-72-6/Cystic Fibrosis Transmembrane Conductance Regulator; 32986-56-4/Tobramycin; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concent...
Next Document: Streptococcus gordonii soluble inorganic pyrophosphatase: an important role for the interdomain regi...